{"id":"NCT02413346","sponsor":"Almirall, S.A.","briefTitle":"A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris","officialTitle":"A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-20","primaryCompletion":"2016-08-26","completion":"2016-08-26","firstPosted":"2015-04-09","resultsPosted":"2018-05-04","lastUpdate":"2019-02-01"},"enrollment":490,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Sarecycline","otherNames":[]}],"arms":[{"label":"Placebo/Sarecycline","type":"EXPERIMENTAL"},{"label":"Sarecycline/Sarecycline","type":"EXPERIMENTAL"}],"summary":"Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.","primaryOutcome":{"measure":"Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)","timeFrame":"Up to 40 Weeks","effectByArm":[{"arm":"Placebo/Sarecycline","deltaMin":94,"sd":null},{"arm":"Sarecycline/Sarecycline","deltaMin":94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":56,"countries":["United States"]},"refs":{"pmids":["32038757"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":236},"commonTop":["Nasopharyngitis"]}}